StackTerminal.Health

NAD+

Nicotinamide adenine dinucleotide precursor supplementation to support cellular energy metabolism and longevity pathways.

goal:longevity-metabolic-cardiovasculargoal:longevitygoal:healthspangoal:metabolicconstraint:drug-test-safeevidence:moderatestudy:rctpop:general-healthy-adultsform:other
Dosing model
FLATFixed dose (no body-weight scaling).
Min dose
250 mg
Max dose
900 mg
Rounding
50 mg
Buy this ingredient← Back

Stacks containing NAD+

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.
Evidence
3 records
NAD+ precursor biology and bioavailability in human tissue
General adults; review of human studies • Systematic review / mechanistic review
Moderate

Supports precursor-to-NAD biology; NR and NMN reliably raise blood NAD+ levels in humans, but whether NAD+ product supplementation (as opposed to precursors) is bioequivalent remains unclear. Evidence does not necessarily establish NAD+ product equivalence.

Dose: —
Citation: Nanga et al. 2024. PMC11436296.
Key mechanistic reference for NAD+ precursor biology.
NAD+ metabolome and aging in humans (NR supplementation)
Healthy adults; aging cohorts • Randomized controlled trial
Moderate

Nicotinamide riboside (NR) supplementation significantly increased whole-blood NAD+ and related metabolites; effects on downstream aging biomarkers were modest and variable across individuals.

Dose: —
Citation: Berven H, et al. A randomized, placebo-controlled study of the effects of nicotinamide riboside on energy metabolism, muscle function, and physical performance in healthy adults. Nat Commun. 2023.
Nat Commun 2023; doi verified.
Blood NAD+ elevation and physical performance (NMN supplementation)
Healthy middle-aged adults (n=80) • Randomized, multicenter, double-blind, placebo-controlled, dose-dependent clinical trial
Moderate

NMN at 300, 600, or 900 mg/day for 60 days significantly increased blood NAD+ vs placebo (p≤0.001). Six-minute walk distance improved significantly at 600–900 mg. Biological age remained stable in NMN groups while increasing in placebo. Well tolerated with no adverse events.

Dose: 600 mg • Duration: 60 days
Citation: Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43.
Dose-dependent NAD+ elevation; clinical significance of performance improvements needs replication in larger trials.